Ionis Pharmaceuticals (IONS) Earns Daily Media Sentiment Rating of 0.11
Media headlines about Ionis Pharmaceuticals (NASDAQ:IONS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ionis Pharmaceuticals earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.7407117214154 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Short Interest in Ionis Pharmaceuticals, Inc. (IONS) Drops By 15.8% (americanbankingnews.com)
- Ionis Pharma (IONS) Says it Retained All Rights to Inotersen and IONIS-FB-LRx (streetinsider.com)
- Nuveen Asset Management LLC Raises Stake in Ionis Pharmaceuticals, Inc. (IONS) (techkenyot.com)
- What’s Next for Ionis Pharmaceuticals Inc (IONS) After Today’s Big Decline? (topactu.net)
- Ionis Pharmaceuticals, Inc. (IONS) Stake Decreased by Pinnacle Associates Ltd (campdesrecrues.com)
A number of brokerages recently weighed in on IONS. Jefferies Group LLC restated an “underperform” rating and set a $18.00 price objective (up previously from $17.00) on shares of Ionis Pharmaceuticals in a research report on Thursday. Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a research report on Wednesday, July 26th. Cowen and Company restated a “market perform” rating on shares of Ionis Pharmaceuticals in a research report on Monday, May 22nd. Stifel Nicolaus boosted their price objective on Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a “hold” rating in a research report on Wednesday. Finally, BMO Capital Markets boosted their price objective on Ionis Pharmaceuticals from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, May 11th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $47.13.
Ionis Pharmaceuticals (NASDAQ IONS) opened at 46.76 on Friday. Ionis Pharmaceuticals has a 52 week low of $24.58 and a 52 week high of $60.01. The stock has a 50 day moving average price of $52.52 and a 200-day moving average price of $46.92. The firm has a market capitalization of $5.80 billion, a P/E ratio of 224.81 and a beta of 3.14.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.03. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 17.34%. The business had revenue of $104.15 million for the quarter, compared to the consensus estimate of $93.29 million. During the same period in the previous year, the firm earned ($0.47) EPS. The company’s revenue was up 170.7% on a year-over-year basis. Analysts anticipate that Ionis Pharmaceuticals will post ($0.02) EPS for the current fiscal year.
In other news, SVP C Frank Bennett sold 10,000 shares of the business’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $59.29, for a total transaction of $592,900.00. Following the completion of the sale, the senior vice president now owns 25,041 shares of the company’s stock, valued at approximately $1,484,680.89. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Stanley T. Crooke sold 16,500 shares of the business’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $52.45, for a total transaction of $865,425.00. Following the sale, the chairman now directly owns 53,014 shares of the company’s stock, valued at approximately $2,780,584.30. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,379 shares of company stock valued at $2,946,052. Insiders own 1.86% of the company’s stock.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.